Valneva SE (NASDAQ:VALN - Get Free Report) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 5,800 shares, a decrease of 84.2% from the February 13th total of 36,700 shares. Based on an average trading volume of 59,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold.
Valneva Trading Up 0.2 %
Shares of VALN traded up $0.02 during trading on Wednesday, reaching $7.08. 3,080 shares of the company traded hands, compared to its average volume of 25,708. The stock has a 50-day simple moving average of $5.97 and a 200-day simple moving average of $5.61. The stock has a market cap of $574.92 million, a PE ratio of -54.65 and a beta of 1.93. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.
Institutional Trading of Valneva
A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in Valneva SE (NASDAQ:VALN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,244 shares of the company's stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Valneva in a research report on Friday, February 28th.
View Our Latest Stock Report on VALN
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
